Six Months After Psilocybin: What the Research Shows About Long-Term Outcomes

If you are doing honest research on psilocybin therapy, you have probably noticed a pattern. The acute experience gets a lot of attention. The long-term question gets less. What actually happens six months later? A year later? Do the changes hold, or does the relief fade?

These are the right questions to ask. And the research, while still early in some respects, now gives us enough data to answer them with more substance than anecdote. Here is a clear-eyed look at what the clinical evidence actually shows about psilocybin lasting results, where the evidence is strong, and where it is still incomplete.

What the Major Studies Found at Follow-Up

The most rigorous long-term data on psilocybin long term effects comes from three institutions that have been tracking participants well beyond the initial treatment period: Johns Hopkins University, NYU Langone Health, and Imperial College London.

Johns Hopkins: 12-Month Depression Data

In a prospective follow-up study published in the Journal of Psychopharmacology in 2022, Johns Hopkins researchers tracked 24 adults with major depressive disorder who had received two psilocybin sessions alongside supportive psychotherapy. Before treatment, participants scored an average of 22.8 on the GRID-Hamilton Depression Rating Scale, placing them in the moderate-to-severe range. At 12 months post-treatment, that average had dropped to 7.7, which falls in the “no depression” range by the same scale.

At the 12-month mark, 75% of participants showed a clinical response, meaning at least a 50% reduction in depression scores from baseline. 58% met full remission criteria. Those numbers held relatively stable across all follow-up points: one month, three months, six months, and twelve months. The durability of that pattern across multiple time points is what makes this study notable, not just any single data point.

NYU: Cancer-Related Distress at 4.5 Years

NYU’s follow-up research covers a different population and a much longer time horizon. The original 2016 trial treated cancer patients experiencing anxiety and depression related to their diagnosis. Researchers then followed up with surviving participants at an average of 3.2 and 4.5 years after their psilocybin session.

At the 4.5-year follow-up, approximately 60 to 80 percent of participants still met criteria for clinically significant antidepressant or antianxiety responses. Between 71 and 100 percent attributed positive life changes to the psilocybin-assisted therapy experience. This was not a population that had repeat sessions or ongoing psychedelic treatment. They received psilocybin once, with psychotherapy, and many were still reporting sustained benefit years later.

This is one of the longest-running follow-up datasets in the field, and it carries weight precisely because the population faced some of the most acute psychological challenges a person can encounter.

Imperial College London: Treatment-Resistant Depression at Six Months

Imperial’s open-label trial focused on a harder-to-treat group: people with mostly severe, unipolar, treatment-resistant depression who had not responded to conventional approaches. Twenty participants received two oral doses of psilocybin with psychological support. The six-month follow-up showed marked reductions in depressive symptoms compared to baseline, with large effect sizes maintained well beyond the initial weeks post-treatment.

This is significant because treatment-resistant depression is, by definition, a condition that has not responded to multiple prior interventions. The fact that a substantial proportion of participants maintained improvement at six months, without ongoing pharmacological treatment, adds meaningful context to how long does psilocybin therapy last in real clinical conditions.

This Is Where Things Get More Nuanced

The data above is real and worth taking seriously. It is also not the full picture.

Across the clinical literature, response and remission rates at follow-up vary considerably from study to study. A 2025 consensus statement from the National Network of Depression Centers noted that in multiple trials, between 29 and 85 percent of participants did not achieve remission. In smaller pilot studies examining treatment-resistant cases, some participants relapsed within weeks, others showed no substantial improvement from the outset, and a smaller group maintained sustained response.

This variability is not a reason to dismiss the research. It is a reason to read it carefully. Psilocybin assisted therapy is not a guaranteed outcome. It is a therapeutic intervention with a meaningful success rate in certain populations, under specific conditions, and those conditions matter.

Several factors appear connected to better long-term outcomes in the existing literature. Two-dose protocols tend to show higher response rates than single-dose approaches. The number of non-dosing sessions, including preparation and integration support, also appears to play a role in how durable the effects are over time. Setting, therapeutic relationship, and the quality of follow-up care all contribute to how psilocybin lasting results unfold.

What Integration Has to Do With It

People often focus on the session itself when asking how long does psilocybin therapy last. That is understandable, but the session is not the whole treatment. The period that follows, typically called integration, is where the insights and shifts from the experience get translated into daily life. This is not a passive process.

In every major clinical trial that has produced durable results, participants had structured psychological support both before and after their psilocybin sessions. At Johns Hopkins, participants had counseling sessions before and after each treatment. At NYU, the model included psychotherapy paired directly with the psilocybin experience. At Imperial, preparation and psychological support were built into the protocol.

None of these studies administered psilocybin in isolation and then walked participants out the door. The integration work, the supported process of making sense of what emerged, appears to be a meaningful part of why the effects persisted.

Without that support structure, the same substance in the same body can produce a very different long-term outcome. This is one of the core reasons that working with a professionally guided approach, rather than pursuing an experience without support, is a practical consideration, not just an ideological one.

What This Looks Like for Real People

Beyond the clinical trials, survey data from Johns Hopkins on naturalistic psilocybin use, published in 2023, found that even outside controlled lab settings, a majority of participants reported persistent reductions in anxiety, depression, and alcohol misuse, along with increased cognitive flexibility and improved emotion regulation over time. These effects were not universal, and unsupported use carries its own risks, but the pattern of sustained benefit across both controlled and naturalistic contexts points in the same direction.

The consistent thread in accounts from both research participants and people who have gone through guided therapeutic experiences is not that psilocybin solved everything. It is that it created an opening, a shift in perspective or emotional accessibility, that required follow-through to become something lasting. The experience initiates. Integration sustains.

Who Is Most Likely to Maintain Long-Term Benefit

Based on what the research currently shows, certain factors are associated with better psilocybin long term effects. These include working within a structured therapeutic framework rather than an unsupported setting, having adequate preparation before the experience, participating in consistent integration work afterward, and having realistic expectations about the process.

People who approach psilocybin therapy as a single event with a fixed outcome tend to be less prepared for the variable and ongoing nature of the work. People who approach it as a significant, professionally supported intervention requiring active engagement before and after tend to report more durable changes.

This is not about optimism or pessimism. It is about what the data actually shows about the conditions under which psilocybin lasting results are most likely to occur.

Where the Research Still Has Limits

It is worth being direct about what the evidence does not yet tell us. Most follow-up studies to date involve relatively small sample sizes. The populations studied are not always representative of the broader range of people who might consider psilocybin therapy. Longer-term follow-up data beyond 12 months for depression specifically remains limited. And the question of whether booster sessions improve durability has not been fully answered.

The research is genuinely promising. It is also still developing. Anyone who tells you the outcomes are certain, in either direction, is moving ahead of the evidence.

What the current data does support is that for a meaningful proportion of people, particularly those working within a structured, professionally supported framework, psilocybin therapy can produce effects that last well beyond the acute experience, sometimes substantially. The six-month and twelve-month data from major institutions reflects this. So does the long-term NYU follow-up at nearly five years.

If you are considering whether this is worth exploring for your own situation, the question is not just whether psilocybin works. It is whether you have access to the kind of supported, well-prepared experience that gives those effects the best chance of lasting.